Home › Funds › Avoro Capital Advisors LLC › COAG
Avoro Capital Advisors LLC position in COAG
HEMAB THERAPEUTICS HLDGS INC · Health Care
Avoro Capital Advisors LLC reported holding 1,892,372 shares of COAG (HEMAB THERAPEUTICS HLDGS INC) in its Q3 2026 13F filing — a position valued at US$58.4M, representing 0.60% of its reported portfolio and ranking #19 among its reported holdings. Avoro Capital Advisors LLC has disclosed COAG holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Avoro Capital Advisors LLC's COAG position evolved
Avoro Capital Advisors LLC first disclosed a stake in COAG in Q2 2026 at 1,925,150 shares (US$70.7M). Across 2 filings, Avoro Capital Advisors LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,892,372 shares valued at US$58.4M — a reduction of -32,778 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.93M | $70.71M | New |
| Q3 2026 | 1.89M | $58.36M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About COAG and 13F data
COAG (HEMAB THERAPEUTICS HLDGS INC) is a Health Care company. 85 other funds we track also report a position in COAG — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$286.8M), Novo Holdings A/S (US$153.6M), Deep Track Capital, LP (US$110.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding COAG
- RA CAPITAL MANAGEMENT, L.P. 7.81M sh · $286.81M · Q2 2026
- Novo Holdings A/S 4.18M sh · $153.55M · Q2 2026
- Deep Track Capital, LP 3.59M sh · $110.65M · Q3 2026
- Siren, L.L.C. 2.37M sh · $72.97M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 1.65M sh · $50.89M · Q3 2026
- Paradigm Biocapital Advisors LP 629.35K sh · $19.41M · Q3 2026
- Rock Springs Capital Management LP 575.43K sh · $17.75M · Q3 2026
- Affinity Asset Advisors, LLC 420.00K sh · $12.95M · Q3 2026
- Parkman Healthcare Partners LLC 329.25K sh · $10.15M · Q3 2026
- Opaleye Management Inc. 47.65K sh · $1.75M · Q2 2026
More on Avoro Capital Advisors LLC
FAQ
How long has Avoro Capital Advisors LLC held COAG?
Avoro Capital Advisors LLC has disclosed COAG holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Avoro Capital Advisors LLC's current position in COAG?
As of Q3 2026, Avoro Capital Advisors LLC holds 1.89M shares of COAG (HEMAB THERAPEUTICS HLDGS INC), valued at $58.36M, representing 0.60% of its reported portfolio and ranking #19.
Has Avoro Capital Advisors LLC been buying or selling COAG?
In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC reduced its position in COAG.
Which other funds hold COAG?
Other major institutional holders of COAG include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, Deep Track Capital, LP, among 85 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.